Influenza Vaccination Among the Elderly Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02362919|
Recruitment Status : Completed
First Posted : February 13, 2015
Last Update Posted : September 11, 2017
|Condition or disease|
This is a population-based prospective cohort study. Potential participants, males and females between 65 and 80 years of age, were selected randomly through the resident registration office in Hannover city, Germany and invited with a personalized letter to participate in the study.
Initially, a blood sample (40 ml) will be drawn from each participant (day 0). Furthermore, participants will be vaccinated against influenza with FLUAD 2014/2015. FLUAD is a trivalent, surface antigen, inactivated influenza virus vaccine adjuvanted with MF59C.1. Additional five blood samples will be collected during the study period of four months (at days 3, 7, 21, 70 and 130). Information about current and past infections, chronic diseases and basic sociodemographic data will be collected through a self-administered questionnaire.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Determinants of Vaccine Response to Influenza Vaccination Among Individuals Over 65 Years of Age - a Population-based Study|
|Actual Study Start Date :||February 2015|
|Actual Primary Completion Date :||May 2016|
|Actual Study Completion Date :||May 2016|
A cohort of elderly individuals
A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
- Serological evidence of vaccine response to influenza vaccination [ Time Frame: 4 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02362919
|Principal Investigator:||Frank Pessler, PD Dr.||Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany|